NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $1.91 -0.04 (-2.05%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$1.92 +0.02 (+0.79%) As of 05:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Autolus Therapeutics Stock (NASDAQ:AUTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Autolus Therapeutics alerts:Sign Up Key Stats Today's Range$1.88▼$1.9750-Day Range$1.40▼$2.5452-Week Range$1.18▼$2.58Volume1.82 million shsAverage Volume1.50 million shsMarket Capitalization$508.37 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Autolus Therapeutics plc (NASDAQ: AUTL) is a biopharmaceutical company developing and commercializing programmed T-cell therapies for cancer and other serious diseases. The company uses genetic engineering to create CAR T-cell products designed to recognize and eliminate cancer cells while improving control, persistence and safety compared with earlier-generation cell therapies. Autolus’ lead product, obecabtagene autoleucel, also known as obe-cel and marketed in the United States as AUCATZYL, is a CD19-directed autologous CAR T-cell therapy. The U.S. Food and Drug Administration approved AUCATZYL in 2024 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus is also advancing additional investigational T-cell therapies for hematologic malignancies and solid tumors, including programs targeting multiple myeloma and neuroblastoma. Founded in 2014 by Professor Martin Pule, Autolus is headquartered in London and conducts research, development and commercial activities in the United States and Europe. The company is led by Chief Executive Officer Christian Itin and continues to expand its pipeline and manufacturing capabilities as it develops next-generation cell therapies.AI Generated. May Contain Errors. Read More Autolus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreAUTL MarketRank™: Autolus Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 134th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAutolus Therapeutics has a consensus price target of $10.00, representing about 423.6% upside from its current price of $1.91.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Autolus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.75) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.21% of the float of Autolus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 4.83.Change versus previous monthShort interest in Autolus Therapeutics has recently decreased by 8.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.05 News SentimentAutolus Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Autolus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,708.00 in company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUTL Stock News HeadlinesAutolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 20, 2026 | americanbankingnews.comAUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The BlackSeptember 12, 2026 | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 25 at 1:00 AM | Weiss Ratings (Ad)Autolus Therapeutics plc: Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus NephritisSeptember 9, 2026 | finanznachrichten.deFDA Grants RMAT Designation To Autolus' Obe-cel For LupusSeptember 9, 2026 | rttnews.comAutolus Receives FDA Regenerative Medicine Advanced Therapy Designation for Obecabtagene AutoleucelSeptember 9, 2026 | finance.yahoo.comAutolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus NephritisSeptember 9, 2026 | globenewswire.comAutolus Therapeutics (NASDAQ:AUTL) Insider Sells 6,713 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $1.99 at the start of the year. Since then, AUTL shares have decreased by 4.0% and is now trading at $1.91. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) released its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.06. The business had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative trailing twelve-month return on equity of 178.66%. Read the conference call transcript. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $141 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 8,823,530 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Top institutional investors of Autolus Therapeutics include Syncona Portfolio Ltd (6.25%), Alphabet Inc. (0.26%), Hennion & Walsh Asset Management Inc. (0.17%) and QRG Capital Management Inc. (0.01%). View institutional ownership trends. How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and Company Calendar Last Earnings8/11/2026Today9/25/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AUTL's financial health is in the Green zone, according to TradeSmith. AUTL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AUTL CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees752Year Founded2014Price Target and Rating Average Price Target for Autolus Therapeutics$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+423.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.53 million Net Margins-238.66% Pretax Margin-238.08% Return on Equity-178.66% Return on Assets-49.34% Debt Debt-to-Equity Ratio1.04 Current Ratio4.89 Quick Ratio4.40 Sales & Book Value Annual Sales$75.39 million Price / Sales6.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book2.85Miscellaneous Outstanding Shares266,160,000Free Float197,759,000Market Cap$508.37 million OptionableOptionable Beta2.10 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AUTL) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
